Higher Prostate Cancer Incidence in the U.S. Leads to Accelerated Drug development Efforts

Higher Prostate Cancer Incidence in the U.S. Leads to Accelerated Drug development Efforts
shutterstock_211842697Cancer is one of the most deadly diseases in the world, with a mortality of 8.2 million people in 2012, as reported by the World Health Organization (WHO). A recent WHO report predicts that the worldwide number of cancer cases diagnosed per year will increase from 14 to 22 million between 2012 and 2032. Prostate cancer (PCa) is one of the most common cancers among men in Western developed countries, including the United States, which has among the higher rates of cases diagnosed per year in the world. In the U.S. in 2013, diagnosed prostate cancer contributed to approximately 239,000 cases, among which, 30,000 men were expected to die due to the disease, as reported by the American Cancer Society. While prostate cancer is not the most deadly type of cancer, it has a significant negative impact on the male population. The prevalence of the prostate cancer within the U.S. states it’s not homogeneous, there are five states with the highest incidence: Louisiana (161.1 incidences per 100,000 men); New Jersey (155.8); Michigan (156.4); Utah (154.4), and New York (154) according with the Centers for Disease Control and Prevention (CDC). While on the national base, the rate of prostate cancer is significantly lower -- 128.3 incidences per 100,000 men. Still, there is no scientific answer for this unusually high incidence of p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *